1. Home
  2. ERAS vs SNDA Comparison

ERAS vs SNDA Comparison

Compare ERAS & SNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • SNDA
  • Stock Information
  • Founded
  • ERAS 2018
  • SNDA 1990
  • Country
  • ERAS United States
  • SNDA United States
  • Employees
  • ERAS N/A
  • SNDA N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • SNDA Hospital/Nursing Management
  • Sector
  • ERAS Health Care
  • SNDA Health Care
  • Exchange
  • ERAS Nasdaq
  • SNDA Nasdaq
  • Market Cap
  • ERAS 396.6M
  • SNDA 462.3M
  • IPO Year
  • ERAS 2021
  • SNDA 1997
  • Fundamental
  • Price
  • ERAS $1.39
  • SNDA $24.78
  • Analyst Decision
  • ERAS Strong Buy
  • SNDA Hold
  • Analyst Count
  • ERAS 6
  • SNDA 1
  • Target Price
  • ERAS $4.83
  • SNDA $25.00
  • AVG Volume (30 Days)
  • ERAS 1.4M
  • SNDA 27.6K
  • Earning Date
  • ERAS 05-20-2025
  • SNDA 05-12-2025
  • Dividend Yield
  • ERAS N/A
  • SNDA N/A
  • EPS Growth
  • ERAS N/A
  • SNDA N/A
  • EPS
  • ERAS N/A
  • SNDA N/A
  • Revenue
  • ERAS N/A
  • SNDA $271,230,000.00
  • Revenue This Year
  • ERAS N/A
  • SNDA $22.33
  • Revenue Next Year
  • ERAS N/A
  • SNDA $6.31
  • P/E Ratio
  • ERAS N/A
  • SNDA N/A
  • Revenue Growth
  • ERAS N/A
  • SNDA 15.80
  • 52 Week Low
  • ERAS $1.01
  • SNDA $19.34
  • 52 Week High
  • ERAS $3.45
  • SNDA $33.75
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 51.46
  • SNDA 64.00
  • Support Level
  • ERAS $1.37
  • SNDA $22.93
  • Resistance Level
  • ERAS $1.61
  • SNDA $24.99
  • Average True Range (ATR)
  • ERAS 0.14
  • SNDA 0.90
  • MACD
  • ERAS 0.00
  • SNDA 0.31
  • Stochastic Oscillator
  • ERAS 45.68
  • SNDA 95.52

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About SNDA Sonida Senior Living Inc.

Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.

Share on Social Networks: